Katharina Elisabeth Blankart

Personal Details

First Name:	Katharina
Middle Name:	Elisabeth
Last Name:	Blankart
Suffix:
RePEc Short-ID:	pfi221
	[This author has chosen not to make the email address public]
	https://katblankart.github.io/
Terminal Degree:	2012 Fakultät für Betriebswirtschaft; Ludwig-Maximilians-Universität München (from RePEc Genealogy)

Affiliation

(95%) Institut für Gesundheitsökonomie und Gesundheitspolitik
Department Gesundheit
Berner Fachhochschule

Bern, Switzerland
https://www.bfh.ch/de/forschung/forschungsbereiche/institut-gesundheitsoekonomie-gesundheitspolitik/
RePEc:edi:igbfhch (more details at EDIRC)

(5%) Deutsches Forschungszentrum für Gesundheitsökonomik (CINCH)
Fachbereich Wirtschaftswissenschaften
Universität Duisburg-Essen

Essen, Germany
https://www.cinch.uni-due.de/
RePEc:edi:cinchde (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:

1. Katharina Elisabeth Blankart & Tom Stargardt, 2020. "The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 63-82, October.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 28th December 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-12-28 12:00:00

Working papers

Sorry, no citations of working papers recorded.

Articles

1. Rucha Vadia & Katharina Blankart, 2021. "Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe," REGION, European Regional Science Association, vol. 8, pages 57-81.

   Cited by:

   1. Timur Gareev & Irina Peker, 2023. "Quantity versus quality in publication activity: knowledge production at the regional level," Papers 2311.08830, arXiv.org.

2. Katharina E. Blankart & Friederike Arndt, 2020. "Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany," IJERPH, MDPI, vol. 17(11), pages 1-14, June.

   Cited by:

   1. Avdic, Daniel & Blankart, Katharina, 2021. "A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany," CINCH Working Paper Series (since 2020) 74978, Duisburg-Essen University Library, DuEPublico.
      • Daniel Avdic & Katharina E. Blankart, 2021. "A hard look at soft cost-control measures in healthcare organizations: Evidence from preferred drug policies in Germany," Papers 2021-07, Centre for Health Economics, Monash University.
   2. Böhm, Anna-Katharina & Steiner, Isa Maria & Stargardt, Tom, 2023. "Market diffusion of biosimilars in off-patent biologic drug markets across Europe," Health Policy, Elsevier, vol. 132(C).

3. Katharina E. Blankart & Frank R. Lichtenberg, 2020. "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, vol. 23(4), pages 605-618, December.

   Cited by:

   1. Di Novi, Cinzia & Leporatti, Lucia & Levaggi, Rosella & Montefiori, Marcello, 2022. "Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 1-14.
   2. Lucia Leporatti & Rosella Levaggi & Marcello Montefiori, 2021. "Beyond price: the effects of non-financial barriers on access to drugs and health outcomes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 519-529, June.

4. Katharina Elisabeth Blankart & Tom Stargardt, 2020. "The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 63-82, October.

   Cited by:

   1. Melanie Büssgen & Tom Stargardt, 2023. "Does health technology assessment compromise access to pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 437-451, April.
   2. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.
   3. Tor Iversen & Ching‐to Albert Ma, 2022. "Technology adoption by primary care physicians," Health Economics, John Wiley & Sons, Ltd., vol. 31(3), pages 443-465, March.

5. Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt, 2018. "The impact of physician-level drug budgets on prescribing behavior," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 213-222, March.

   Cited by:

   1. Katharina E. Blankart & Friederike Arndt, 2020. "Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany," IJERPH, MDPI, vol. 17(11), pages 1-14, June.
   2. Berger, Michael & Pock, Markus & Reiss, Miriam & Röhrling, Gerald & Czypionka, Thomas, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation," LSE Research Online Documents on Economics 116928, London School of Economics and Political Science, LSE Library.
   3. Mills, Mackenzie & Kanavos, Panos, 2020. "Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe," Health Policy, Elsevier, vol. 124(3), pages 239-251.
   4. Michael Berger & Markus Pock & Miriam Reiss & Gerald Röhrling & Thomas Czypionka, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms," International Journal of Health Economics and Management, Springer, vol. 23(1), pages 149-172, March.
   5. Avdic, Daniel & Blankart, Katharina, 2021. "A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany," CINCH Working Paper Series (since 2020) 74978, Duisburg-Essen University Library, DuEPublico.
      • Daniel Avdic & Katharina E. Blankart, 2021. "A hard look at soft cost-control measures in healthcare organizations: Evidence from preferred drug policies in Germany," Papers 2021-07, Centre for Health Economics, Monash University.
   6. Katharina Elisabeth Blankart & Tom Stargardt, 2020. "The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 63-82, October.
   7. Sara Mucherino & Manuela Casula & Federica Galimberti & Ilaria Guarino & Elena Olmastroni & Elena Tragni & Valentina Orlando & Enrica Menditto & on behalf of the EDU.RE.DRUG Group, 2022. "The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review," IJERPH, MDPI, vol. 19(11), pages 1-19, May.

6. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.

   Cited by:

   1. Niehaus, Ines & Dintsios, Charalabos-Markos, 2018. "Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs," Health Policy, Elsevier, vol. 122(6), pages 599-606.
   2. Anderson, Michael & Drummond, Michael & Taylor, David & McGuire, Alistair & Carter, Paul & Mossialos, Elias, 2022. "Promoting innovation while controlling cost: The UK's approach to health technology assessment," Health Policy, Elsevier, vol. 126(3), pages 224-233.
   3. Visintin, Erica & Tinelli, Michela & Kanavos, Panos, 2019. "Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries," Health Policy, Elsevier, vol. 123(2), pages 118-129.
   4. Chris Skedgel & Dominika Wranik & Min Hu, 2018. "The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian On," PharmacoEconomics, Springer, vol. 36(4), pages 467-475, April.
   5. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.
   6. C. M. Dintsios & F. Worm & J. Ruof & M. Herpers, 2019. "Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree," Health Economics Review, Springer, vol. 9(1), pages 1-15, December.
   7. Blankart, Carl Rudolf & Dams, Florian & Penton, Hannah & Kaló, Zoltán & Zemplényi, Antal & Shatrov, Kosta & Iskandar, Rowan & Federici, Carlo, 2021. "Regulatory and HTA early dialogues in medical devices," Health Policy, Elsevier, vol. 125(10), pages 1322-1329.
   8. Mills, Mackenzie & Kanavos, Panos, 2022. "How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada," Health Policy, Elsevier, vol. 126(11), pages 1130-1143.

7. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.

   Cited by:

   1. Guhl, Dennis & Stargardt, Tom & Schneider, Udo & Fischer, Katharina E., 2016. "Dispensing behaviour of pharmacies in prescription drug markets," Health Policy, Elsevier, vol. 120(2), pages 190-197.
   2. Afschin Gandjour & Dennis A. Ostwald, 2018. "Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany," PharmacoEconomics, Springer, vol. 36(10), pages 1285-1296, October.
   3. Fiorentini, Gianluca & Bruni, Matteo Lippi & Mammi, Irene, 2022. "The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 37-68.
   4. Frank R. Lichtenberg, 2022. "The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017," Journal of Evolutionary Economics, Springer, vol. 32(4), pages 1155-1173, September.
   5. Böhm, Anna-Katharina & Steiner, Isa Maria & Stargardt, Tom, 2023. "Market diffusion of biosimilars in off-patent biologic drug markets across Europe," Health Policy, Elsevier, vol. 132(C).

8. Katharina E. Fischer & Tom Stargardt, 2014. "Early Benefit Assessment of Pharmaceuticals in Germany," Medical Decision Making, , vol. 34(8), pages 1030-1047, November.

   Cited by:

   1. Giulini-Limbach, Chiara & Bauer, Cosima & May, Uwe, 2021. "Arzneimittelmarkt-Steuerung unter dem Einfluss von AMNOG und Festbeträgen: Forschungsprojekt im Auftrag der Bristol-Myers Squibb GmbH & Co. KGaA," IBES Diskussionsbeiträge 232, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).
   2. Böhler, Yvonne-Beatrice & Lamping, Christian & Wichardt, Philipp C., 2019. "Pharmaceutical prices: The impact of the launch strategy. An analysis of German data," Kiel Working Papers 2141, Kiel Institute for the World Economy (IfW Kiel).
   3. Yvonne-Beatrice Böhler & Christian Lamping & Philipp Christoph Wichard & Philipp Christoph Wichardt, 2019. "Pharmaceutical Prices: The Impact of the Launch Strategy - An Analysis of German Data," CESifo Working Paper Series 7879, CESifo.
   4. Katharina Elisabeth Blankart & Tom Stargardt, 2020. "The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 63-82, October.

9. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.

   Cited by:

   1. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
   2. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.

10. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.

    Cited by:

    1. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    2. Katharina Elisabeth Fischer & Wolf Henning Rogowski, 2014. "Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe," IJERPH, MDPI, vol. 11(5), pages 1-28, May.
    3. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    4. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    5. Chris Schilling & Duncan Mortimer & Kim Dalziel, 2017. "Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions," Medical Decision Making, , vol. 37(2), pages 173-182, February.
    6. Wolf Rogowski & Katherine Payne & Petra Schnell-Inderst & Andrea Manca & Ursula Rochau & Beate Jahn & Oguzhan Alagoz & Reiner Leidl & Uwe Siebert, 2015. "Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation," PharmacoEconomics, Springer, vol. 33(1), pages 49-59, January.

11. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.

    Cited by:

    1. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    2. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
    3. Karin Cerri & Martin Knapp & Jose-Luis Fernandez, 2014. "Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 681-695, September.
    4. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    5. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
    6. Anna Nicolet & Antoinette D I van Asselt & Karin M Vermeulen & Paul F M Krabbe, 2020. "Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    7. Hwa-Young Lee & Thuy Thi-Thu Nguyen & Saeun Park & Van Minh Hoang & Woong-Han Kim, 2021. "Health Technology Assessment Development in Vietnam: A Qualitative Study of Current Progress, Barriers, Facilitators, and Future Strategies," IJERPH, MDPI, vol. 18(16), pages 1-13, August.
    8. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    9. Kleinhout-Vliek, Tineke & de Bont, Antoinette & Boer, Bert, 2017. "The bare necessities? A realist review of necessity argumentations used in health care coverage decisions," Health Policy, Elsevier, vol. 121(7), pages 731-744.
    10. Chris Schilling & Duncan Mortimer & Kim Dalziel, 2017. "Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions," Medical Decision Making, , vol. 37(2), pages 173-182, February.
    11. Nicod, Elena & Kanavos, Panos, 2016. "Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study," Health Policy, Elsevier, vol. 120(1), pages 35-45.
    12. Katharina E. Fischer & Tom Stargardt, 2014. "Early Benefit Assessment of Pharmaceuticals in Germany," Medical Decision Making, , vol. 34(8), pages 1030-1047, November.
    13. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
    14. Hostenkamp, Gisela & Fischer, Katharina Elisabeth & Borch-Johnsen, Knut, 2016. "Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark," Health Policy, Elsevier, vol. 120(12), pages 1404-1411.

12. Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H., 2011. "A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention," Health Policy, Elsevier, vol. 101(3), pages 290-299, August.

    Cited by:

    1. Katharina Elisabeth Fischer & Wolf Henning Rogowski, 2014. "Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe," IJERPH, MDPI, vol. 11(5), pages 1-28, May.
    2. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
    3. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    4. Katharina E. Fischer & Björn Stollenwerk & Wolf H. Rogowski, 2013. "Link between Process and Appraisal in Coverage Decisions," Medical Decision Making, , vol. 33(8), pages 1009-1025, November.
    5. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 3 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.

1. NEP-HEA: Health Economics (2) 2021-11-22 2022-10-10
2. NEP-EUR: Microeconomic European Issues (1) 2021-11-22
3. NEP-IAS: Insurance Economics (1) 2021-11-22
4. NEP-LAW: Law and Economics (1) 2021-11-22

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Katharina Elisabeth Blankart should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.